ClinicalTrials.Veeva

Menu

Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM

U

Unity Health Toronto

Status and phase

Completed
Phase 2

Conditions

Coronary Heart Disease
Type2 Diabetes

Treatments

Dietary Supplement: wheat bran
Dietary Supplement: konjac glucomannan

Study type

Interventional

Funder types

Other

Identifiers

NCT03741660
Konjac in T2DM

Details and patient eligibility

About

To examine whether Konjac-mannan fiber improves metabolic control measured by glycemia, lipidemia, and blood pressure in individuals with type-2 diabetes.

Enrollment

11 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • hyperlipidemia controlled by medication
  • hypertension controlled by medication
  • type 2 diabetes controlled by medication
  • minimum 3 years since onset of all three conditions
  • sedentary lifestyle

Exclusion criteria

  • regular smoking
  • regular alcohol consumption
  • family history of premature coronary heart disease
  • hypothyroidism
  • renal, hepatic or gastrointestinal disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

11 participants in 2 patient groups, including a placebo group

Konjac-mannan
Experimental group
Description:
Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
Treatment:
Dietary Supplement: konjac glucomannan
Placebo
Placebo Comparator group
Description:
wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
Treatment:
Dietary Supplement: wheat bran

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems